The American Society of Clinical Oncology has made public its detailed guidance to CMS, supporting implementation of physician-focused and other alternative payment models under MACRA.
When President Obama signed legislation authorizing the Medicare Access and CHIP Reauthorization Act or MACRA to replace the much-despised sustainable growth rate formula, commonly known as SGR, on April 16, 2015, a big sigh of relief could be heard from providers. Praising the lawmakers who worked toward avoiding the 21% reimbursement cut under SGR—since the formula was linked to the gross domestic product—Obama said, “This bill is consistent with that proposal — it’s a milestone for physicians, and for the seniors and people with disabilities who rely on Medicare for their health care needs.”
In response to CMS’ request for information, the American Society of Clinical Oncology (ASCO) has made public its detailed guidance to the federal body, supporting implementation of physician-focused and other alternative payment models (APMs) under MACRA.
In a press release summarizing the guiding principles developed by ASCO, the organization’s President Julie Vose, MD, MBA, FASCO, said, “As CMS works to transform the Medicare physician reimbursement system, we provided—and will continue to provide—the agency with robust feedback based on what we've learned over many years from ASCO's payment reform efforts.”
The following are the 11 guiding principles provided by ASCO to CMS that would ensure a sustainable Medicare payment system in clinical oncology:
Vose is the keynote speaker at The American Journal of Managed Care’s Patient-Centered Oncology Care 2015 meeting in Baltimore, being held November 19-20, 2015.
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
Polypharmacy Common in Rheumatoid Arthritis, Driving Risk of Serious Drug Interactions
August 13th 2025More than 8 in 10 patients with rheumatoid arthritis were taking 5 or more medications at once, a practice linked to older age, multiple comorbidities, and more than 2000 potential drug-to-drug interactions.
Read More